Search

Meeting report | HOPE ASIA 2019 Kolkata

The first edition of the Highlights of Past EHA (HOPE) in Asia was held in Kolkata, India and was a great success.

Read more

Join EHA and SIE and receive up to €50 discount on your EHA membership

We are pleased to inform you that EHA and the Società Italiana di Ematologia (SIE) have joined forces and are offering you the possibility of an EHA-SIE Joint Membership.

Read more

Genome sequencing of thousands of patients with rare blood disorders

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot. The genetic causes of dozens of such disorders are known (e. g.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Clinical Research Training in Hematology

The CRTH 2025 call for applications is open until August 30, 2024 (12:00 CEST).

Read more

Turkey tutorial focused on lymphoma

The 8th EHA-TSH Hematology Tutorial was held on April 6-7, 2019 in Izmir, Turkey. This marks yet another pleasant and fruitful collaboration between EHA and the Turkish Society of Hematology.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more